Roche’s Vabysmo receives US FDA approval to treat retinal vein occlusion
Roche announced that the United States Food and Drug Administration (FDA) has approved Vabysmo (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO).
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME). Together, the three retinal conditions affect around 70 million people worldwide and are among the leading causes of vision loss.
“Vabysmo is a new treatment option for RVO that can help people preserve and improve their vision, with the added benefit of retinal drying,” said Levi Garraway, M.D., Ph.D., Roche’s chief medical officer and head of global product development. “The efficacy and safety profile of Vabysmo has been well established in global clinical trials and is reinforced by a growing breadth of real-world evidence, with hundreds of thousands of people treated.”
